IGFBP7 and neoplasm: By providing information on the degree of tumour angiogenesis and related clinical aggressiveness, the anti-IGFBP7 sdAb could also be used to assess/monitor efficacy of anti-angiogenic or other anti-tumour treatments, and thus improve the clinical management of brain tumours.